Actuate TherapeuticsACTU -14.29%14 EBIT per Share is $-0.99 as of Mar. 2026. GuruFocus rates ACTU with a GF Score™ of 14/100. Among 1,184 Biotechnology companies, Actuate Therapeutics ranks worse than 60.81% on this metric.
Actuate Therapeutics's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.24.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.99.
During the past 3 years, the average EBIT per Share Growth Rate was 7.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Actuate Therapeutics's EBIT per Share or its related term are showing as below:
ACTU'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 7.3 Med: 7.3 Max: 7.3
Current: 7.3
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Actuate Therapeutics was 7.30% per year. The lowest was 7.30% per year. And the median was 7.30% per year.
ACTU's 3-Year EBIT Growth Rate is ranked worse than 60.81% of 1184
companies
in the Biotechnology industry
Industry Median: 15.45
vs ACTU: 7.30
Actuate Therapeutics (NAS:ACTU) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Actuate Therapeutics EBIT per Share Related Terms
Actuate Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Actuate Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.99
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Actuate Therapeutics (ACTU) has a EBIT per Share of $-0.99 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Actuate Therapeutics and its competitors. According to the industry distribution chart, Actuate Therapeutics ranks #720 out of 1184 companies in the Biotechnology industry, placing it in the top 60.8%.
Is Actuate Therapeutics' EBIT per Share too high?
Actuate Therapeutics' current EBIT per Share is $-0.99. Based on the distribution chart, Actuate Therapeutics ranks #720 out of 1184 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' EBIT per Share compare to AURX and ESLA?
According to the Biotechnology industry distribution chart, Actuate Therapeutics ranks #720 out of 1184 companies for EBIT per Share. This places Actuate Therapeutics in the lower half of its industry. The industry median EBIT per Share is 15.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.45, based on 1,184 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Actuate Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Actuate Therapeutics's current EBIT per Share is $-0.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current EBIT per Share of $-0.99. The current EBIT per Share is $-0.99. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current EBIT per Share is $-0.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score
Get the complete analysis for ACTU
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACTU has been successfully added to your 
